title: Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study.
abstract: We conducted a multicenter, phase II trial to investigate the efficacy and safety of rituximab plus CVP (R-CVP) combination therapy for patients with previously untreated stage III or IV marginal zone lymphoma (MZL). The treatment consisted of rituximab 375 mg/m(2), cyclophosphamide 750 mg/m(2) and vincristine 1.4 mg/m(2) (maximum 2.0 mg) being given intravenously on day 1 and oral prednisolone 100 mg on days 1-5. The treatment was repeated every 3 weeks and this was continued for six or eight cycles. Forty-two patients were enrolled from 13 institutes in Korea. Among them, two patients were dropped after the first and second cycles of chemotherapy, respectively, without evaluation. The 40 patients received a total of 287 cycles of R-CVP chemotherapy. The overall response rate was 88% (95% CI, 77-98%) with 24 complete responses (60%). The median duration of response was 28.3 months. After a median follow-up of 38.2 months, the estimated 3-year progression-free survival and overall survival were 59% and 95%, respectively. There were 30/287 cycles (11%) and 5/287 cycles (2%) of grade 3 or 4 neutropenia and febrile neutropenia, respectively. The R-CVP regimen can be an effective and tolerable first-line immunochemotherapy regimen for advanced stage MZL.
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, 75 Nowon Gil, Nowon-gu, Seoul 139-706, Republic of Korea.
authors.forename: Hye Jin
authors.initials: HJ
authors.lastname: Kang
authors.forename: Won Seog
authors.initials: WS
authors.lastname: Kim
authors.forename: Seok Jin
authors.initials: SJ
authors.lastname: Kim
authors.forename: Je-Jung
authors.initials: JJ
authors.lastname: Lee
authors.forename: Deok-Hwan
authors.initials: DH
authors.lastname: Yang
authors.forename: Jin Seok
authors.initials: JS
authors.lastname: Kim
authors.forename: Se-Ryeon
authors.initials: SR
authors.lastname: Lee
authors.forename: Gyeong-Won
authors.initials: GW
authors.lastname: Lee
authors.forename: Hyo Jung
authors.initials: HJ
authors.lastname: Kim
authors.forename: Ho Young
authors.initials: HY
authors.lastname: Kim
authors.forename: Sung Yong
authors.initials: SY
authors.lastname: Oh
authors.forename: Hugh Chul
authors.initials: HC
authors.lastname: Kim
authors.forename: Hyeon-Seok
authors.initials: HS
authors.lastname: Eom
authors.forename: Jooseop
authors.initials: J
authors.lastname: Chung
authors.forename: Jinny
authors.initials: J
authors.lastname: Park
authors.forename: Cheolwon
authors.initials: C
authors.lastname: Suh
authors.forename: Baek-Yeol
authors.initials: BY
authors.lastname: Ryoo
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination / Q000379:methods*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use*; D056910:Republic of Korea; D000069283:Rituximab; D015996:Survival Rate; D014750:Vincristine / Q000627:therapeutic use*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D005938:Glucocorticoids; D000069283:Rituximab; D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone